Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Kestra Medical Technologies, Ltd.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $28.27, Kestra Medical Technologies, Ltd. trades at 15.8x sales and 7.4x book value. Over the last twelve months it generated about $107M of revenue and a net loss of $159M. It runs a gross margin of 53.9%, an operating margin of -134.5% and a net margin of -140.4%. It shows return on equity of -64.2%, return on invested capital of -48.0% and a free cash flow yield of -7.3%. On the balance sheet: a debt-to-equity ratio of 0.34 and a current ratio of 4.69. Over the past 52 weeks the share price ranged from $17.34 to $31.99, with a beta of 0.62.
Kestra Medical Technologies, Ltd. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 3 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of July 2026, Kestra Medical Technologies, Ltd. (KMTS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.55% / 30% · (Cash+Inv) / Mkt Cap (36m) 15.4% / 30% · Interest income / Revenue -6.86% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 4.55% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.5% / 33% · Receivables / Mkt Cap (36m) 0.97% / 49% · Interest income / Revenue -6.86% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 4.55% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.5% / 33.33% · Receivables / Mkt Cap (24m) 0.97% / 33.33% · Interest income / Revenue -6.86% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 15.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 64.7% / 33.33% · Receivables / Avg Assets (4Q) 3.98% / 33.33% · Interest income / Revenue -6.86% / 5% | Fail |
| FTSE | Debt / Total Assets 20.9% / 33.33% · (Cash+ST Inv) / Total Assets 57.3% / 33.33% · (Cash+Recv) / Total Assets 61.7% / 33.33% · Interest income / Revenue -6.86% / 5% | Fail |
It depends on the standard you follow. As of July 2026, Kestra Medical Technologies, Ltd. (KMTS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Kestra Medical Technologies, Ltd. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Kestra Medical Technologies, Ltd. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated July 31, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.